Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample
ABSTRACT Background Catheter ablation is a key treatment for atrial fibrillation (AF). This procedure is clearly identifiable in French medical‐administrative databases and can be used as a surrogate for symptomatic patients with drug‐refractory or symptomatic paroxysmal AF forms. Breast cancer (BC)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222381602603008 |
|---|---|
| author | Laura Saint‐Lary Juliette Thariat Baptiste Pinel Gaëlle Jimenez Marie‐Odile Bernier Loïc Panh Serge Boveda Sophie Jacob |
| author_facet | Laura Saint‐Lary Juliette Thariat Baptiste Pinel Gaëlle Jimenez Marie‐Odile Bernier Loïc Panh Serge Boveda Sophie Jacob |
| author_sort | Laura Saint‐Lary |
| collection | DOAJ |
| description | ABSTRACT Background Catheter ablation is a key treatment for atrial fibrillation (AF). This procedure is clearly identifiable in French medical‐administrative databases and can be used as a surrogate for symptomatic patients with drug‐refractory or symptomatic paroxysmal AF forms. Breast cancer (BC) patients have an increased risk of AF, but knowledge about AF forms treated by ablation is limited. Aims Based on a representative cohort of BC patients from the French National Health Databases, we aimed to assess the occurrence of AF catheter ablation in these patients, compared to the general population. Methods Patients with a first diagnosis of BC between 2008 and 2018 and followed for at least 1 year until 2019 were eligible. The incidence rates of AF ablation among BC patients were compared to those in the general population by estimating a standardized incidence ratio (SIR). A competing risk survival model was used to evaluate the occurrence of AF ablation in BC patients treated with or without radiotherapy (RT) (subdistribution Hazard Ratio—sdHR). Results We included 3667 patients (78% with RT). Overall, 16 cases underwent AF ablation, whereas 8.3 cases were expected in the general population, resulting in a significant SIR of 1.93 [1.10–3.00] (p < 0.05). After a mean follow‐up of 6.6 years, the cumulative incidence of AF ablation at 5 years was 0.14% [0.05–0.35] in the RT group and 0.47% [0.13–1.31] in the non‐RT group, with no significant difference in the age‐adjusted survival analysis (sdHR = 0.65 [0.21–2.01]). Conclusions Our exploratory study revealed that BC patients had a twofold greater rate of first AF ablation than the age‐comparable general population, without a link with RT. These results should be interpreted cautiously because of the limited size of the study population and the differing characteristics between the RT and non‐RT groups. |
| format | Article |
| id | doaj-art-71e00144e4ce41bfa8bd1bc1012e2846 |
| institution | Kabale University |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-71e00144e4ce41bfa8bd1bc1012e28462025-08-26T06:00:42ZengWileyCancer Reports2573-83482025-08-0188n/an/a10.1002/cnr2.70320Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database SampleLaura Saint‐Lary0Juliette Thariat1Baptiste Pinel2Gaëlle Jimenez3Marie‐Odile Bernier4Loïc Panh5Serge Boveda6Sophie Jacob7Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE‐SANTE/SESANE/LEPID, Laboratoire D'épidémiologie Fontenay‐aux‐Roses FranceDepartment of Radiation Oncology Comprehensive Cancer Centre François Baclesse Caen FranceDepartment of Radiation Oncology Clinique Pasteur Toulouse FranceDepartment of Radiation Oncology Clinique Pasteur Toulouse FranceAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE‐SANTE/SESANE/LEPID, Laboratoire D'épidémiologie Fontenay‐aux‐Roses FranceDepartment of Cardiology and Heart Rhythm Management Clinique Pasteur Toulouse FranceDepartment of Cardiology and Heart Rhythm Management Clinique Pasteur Toulouse FranceAutorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE‐SANTE/SESANE/LEPID, Laboratoire D'épidémiologie Fontenay‐aux‐Roses FranceABSTRACT Background Catheter ablation is a key treatment for atrial fibrillation (AF). This procedure is clearly identifiable in French medical‐administrative databases and can be used as a surrogate for symptomatic patients with drug‐refractory or symptomatic paroxysmal AF forms. Breast cancer (BC) patients have an increased risk of AF, but knowledge about AF forms treated by ablation is limited. Aims Based on a representative cohort of BC patients from the French National Health Databases, we aimed to assess the occurrence of AF catheter ablation in these patients, compared to the general population. Methods Patients with a first diagnosis of BC between 2008 and 2018 and followed for at least 1 year until 2019 were eligible. The incidence rates of AF ablation among BC patients were compared to those in the general population by estimating a standardized incidence ratio (SIR). A competing risk survival model was used to evaluate the occurrence of AF ablation in BC patients treated with or without radiotherapy (RT) (subdistribution Hazard Ratio—sdHR). Results We included 3667 patients (78% with RT). Overall, 16 cases underwent AF ablation, whereas 8.3 cases were expected in the general population, resulting in a significant SIR of 1.93 [1.10–3.00] (p < 0.05). After a mean follow‐up of 6.6 years, the cumulative incidence of AF ablation at 5 years was 0.14% [0.05–0.35] in the RT group and 0.47% [0.13–1.31] in the non‐RT group, with no significant difference in the age‐adjusted survival analysis (sdHR = 0.65 [0.21–2.01]). Conclusions Our exploratory study revealed that BC patients had a twofold greater rate of first AF ablation than the age‐comparable general population, without a link with RT. These results should be interpreted cautiously because of the limited size of the study population and the differing characteristics between the RT and non‐RT groups.https://doi.org/10.1002/cnr2.70320catheter ablationdata claimsepidemiologyradiotherapybreast cancer |
| spellingShingle | Laura Saint‐Lary Juliette Thariat Baptiste Pinel Gaëlle Jimenez Marie‐Odile Bernier Loïc Panh Serge Boveda Sophie Jacob Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample Cancer Reports catheter ablation data claims epidemiology radiotherapybreast cancer |
| title | Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample |
| title_full | Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample |
| title_fullStr | Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample |
| title_full_unstemmed | Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample |
| title_short | Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample |
| title_sort | catheter ablation for atrial fibrillation in breast cancer survivors an exploratory observational study using the french nationwide health care database sample |
| topic | catheter ablation data claims epidemiology radiotherapybreast cancer |
| url | https://doi.org/10.1002/cnr2.70320 |
| work_keys_str_mv | AT laurasaintlary catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT juliettethariat catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT baptistepinel catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT gaellejimenez catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT marieodilebernier catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT loicpanh catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT sergeboveda catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample AT sophiejacob catheterablationforatrialfibrillationinbreastcancersurvivorsanexploratoryobservationalstudyusingthefrenchnationwidehealthcaredatabasesample |